Ozempic among ‘bogus’ drug patents being challenged by U.S. to spur competition
Global News
The Federal Trade Commission sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions.
Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest effort by the Biden administration targeting pharmaceutical industry practices that drive up prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
“By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on,” said FTC Chair Lina Khan, in a statement.
Ozempic is part of a class of drugs that were originally developed to treat diabetes but which have recently been approved to treat obesity, generating a surge in prescribing. Medicare spending on the drugs has also spiked in recent years.
The drug’s Danish manufacturer, Novo Nordisk, declined to comment.
FTC’s latest announcement follows a similar action in September when regulators challenged more than 100 patents held by drugmakers, including Abbvie, AstraZeneca and Boehringer Ingelheim.
Companies receiving the letters have 30 days to withdraw or update their patent listings, or “certify under penalty of perjury” that they are legitimate, according to the FTC. The patents are registered with the Food and Drug Administration, which reviews and approves new drugs.
The motion won't mean the city is investing or accepting payment in cryptocurrency any time soon, but will instead direct staff to look into those possibilities.
Enbridge officials said in a statement that the reroute proposal has gone through rigorous reviews and studies.
A proposed deal that would see three tobacco giants pay out billions to provinces and territories, as well as smokers across Canada, has been approved by the companies' creditors.
Tokyo recently announced a four-day workweek policy in an effort to boost Japan’s record-low fertility rate - something that Canada is also struggling with.
More than 1,500 firefighters were battling the blaze, many working in steep canyons, according to the California Department of Forestry and Fire Protection, known as Cal Fire.
Evidence has grown in recent years that highly processed foods are linked to a wide range of chronic health problems, like diabetes and heart disease.
Environment and Climate Change Canada has released its list of the top 10 most impactful weather events of 2024.
Fifteen charges under the federal Fisheries Act have been laid against Imperial Metals Corp. more than 10 years after a tailings pond collapsed the Mount Polley mine.
Many kids and teens are looking forward to the holidays with great excitement, but others find it a difficult time of year filled with anxiety, stress and loneliness. It’s something Alisa Simon, the chief youth officer at Kids Help Phone, says they watch for when school pauses for the winter break, noting, “we do see an increase...
Advocates and friends of a Nova Scotia woman who died from stage IV breast cancer are urging the province to update its screening policy for women with dense breast tissue.
The report estimates a cancer patient will face almost $33,000 on average in out-of-pocket cancer-related costs in their lifetime, including loss of income.